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Abstract
Background: MicroRNAs (miRNAs) have been suggested to play a vital role in tumor initiation and progression by
negatively regulating oncogenes and tumor suppressors. Quite recently, studies have identified some miRNAs
operating to promote or suppress tumor invasion or metastasis via regulating metastasis-related genes, providing
potential therapeutic targets on anti-metastasis strategy. Metastasis-associated in colon cancer-1 (MACC1) has been
newly identified to express highly in colorectal cancer (CRC) and promote tumor metastasis through transactivating
metastasis-inducing HGF/MET signaling pathway. In this study, we investigated whether miRNA 143 is involved in
the regulation of MACC1 and thus plays a functional role in CRC.
Results: Using both in silico prediction and western blot assay, we found the previously reported tumor
suppressive miR-143 targeted MACC1 in CRC. The direct interaction between them was confirmed by 3’ UTR
luciferase reporter gene. In concordance with the inhibitory effects induced by siRNA mediated knockdown of
MACC1, restoration of miR-143 by mimics in SW620 cells significantly attenuated cell growth, migration and
invasion. It is notable that combined treatment of miR-143 mimics and MACC1 siRNA induced synergistic inhibitory
effects compared to either miR-143 mimics or MACC1 siRNA treatment alone. Conversely, reduction of miR-143 by
inhibitors in SW480 cells apparently stimulated these phenotypes. Furthermore, we observed that miR-143 level
was inversely correlated with MACC1 mRNA expression in CRC tissues.
Conclusions: Our findings newly described miR-143/MACC1 link and provided a potential mechanism for MACC1
dysregulation and contribution to CRC cell invasion. It may help to estimate the therapeutic utility of miR-143 in
CRC.
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Introduction
Colorectal cancer (CRC) is the third most common can-
cer and the second leading cause of cancer-related
deaths in western countries [1], with very poor prog-
nosis and high possibilities of tumor invasion and
migration. Although invasion and migration have been
acknowledged as the most lethal attributes of solid
tumors, the molecular mechanism underlying them is
still limited.
Recently, growing evidences have supported the can-
cer-related effects of miRNAs, a newly discovered class
of non-coding small RNA which functions through
negatively regulating a variety of gene expression.
Mature miRNAs exert effects by integrating into an
RNA-inducing silencing complex (RISC) and binding to
specific complementary sites within 3’ untranslated
regions (3’UTR) of their target genes mRNA, to inhibit
translation or directly induce degradation [2-5]. Bioin-
formatic algorithms assess that all the human miRNAs
may regulate up to 30% of human genes which repre-
sent the majority of genetic pathways [6,7]. Many stu-
dies have identified specific miRNAs expression profiles
of multiple cancer types compared to those of normal
adjacent tissues. Depending on cellular contexts and tar-
get genes that they regulate, miRNAs may function as
tumor suppressors or oncogenes [8,9]. Among these
functional miRNAs, miR-143 has been demonstrated to
significantly decrease in multiple cancer types and play
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a role of tumor suppressor. For instance, loss of miR-
143 was observed in bladder cancer, whereas enhanced
expression of miR-143 induced growth suppression in
bladder cancer cells through downregulation of Erk5
and Akt expression at translational level [10]. Moreover,
miR-143 was validated to inhibit prostate cancer cells
proliferation and migration and enhance their sensitivity
to docetaxel through suppressing K-RAS [11]. In CRC,
Micheal et al. [12] reported that miR-143 consistently
displays reduced steady-state levels at the adenomatous
and cancer stages of CRC. K-RAS and DNMT3A gene
were subsequently identified to be regulated by miR-
143, which partly explained the inhibitory effect of miR-
143 on CRC growth [13,14]. Besides, a clinical study
found that, compared to adjacent normal colon tissues,
miR-143 exhibited a lower expression in colorectal liver
metastases as well as that in primary tumor [15], which
implied the involvement of miR-143 in CRC invasion
and metastasis.
Metastasis-associated in colon cancer-1 (MACC1), a
newly identified CRC tumorigenesis and metastasis
related gene, has recently been identified to act as a key
activator of the metastasis-inducing HGF/Met signaling
pathway, promoting proliferation, invasion and HGF-
induced scattering of CRC cells in cell culture and
tumor growth and metastasis in xenograft models [16].
Several studies demonstrated that, besides in CRC,
MACC1 could serve as an independent prognostic mar-
ker of tumor invasiveness and metastasis in some other
cancer types [17-19]. Existing data regarding the invol-
vement of MACC1 in tumor metastasis also suggest its
particular therapeutic impact.
In the present study, we confirmed the regulatory rela-
tionship between miR-143, a known tumor suppressive
miRNA, and a new oncogene, MACC1. We provided
evidences that miR-143 could impede CRC cell invasion
and migration, at least partly by targeting MACC1.
Furthermore, the correlation between miR-143 and
MACC1 expression level in CRC was determined.
Results
miR-143 is frequently downregulated in CRC tissues and
cell lines
We performed SYBR green quantitative PCR analysis to
detect the expression level of miR-143 in CRC tissues
and cell lines. In the large panel of 30 cases of primary
CRC tissues and their adjacent normal colonic tissues,
our results showed that miR-143 was significantly
decreased in 23 (76.6%) CRC tissues when compared
with that in the paired adjacent normal tissues (Figure
1A). In addition, we extended our test to six human
CRC cell lines. The total six cell lines showed a notable
loss of miR-143, whereas the control normal colonic
mucosa pooled from 3 healthy individuals expressed a
strong level of it (Figure 1B).
miR-143 directly targets MACC1
Using online miRNA target prediction databases
(miRNA.org and Targetscan), we hypothesized that
metastasis-associated in colon cancer-1 (MACC1),
which has been newly identified as a positive prognostic
indicator of metastasis formation in CRC [16], was a tar-
get of miR-143 (Figure 2A). We first examined the
MACC1 expression profile in the panel of six CRC cell
lines. Western blot analysis showed that both the metas-
tasis-derived LoVo and SW620 cells had notable
MACC1 expression as well as HT29 and Caco-2 cells
(Figure 2B). SW480 and SW620 cell lines are derived
from the primary colon adenocarcinoma and a node
metastasis resected from a single patient respectively
[20]. It has been reported that SW620 cells were more
highly metastatic than some other CRC cell lines includ-
ing SW480 cells [21,22]. Since SW480 cells showed
Figure 1 Decreased expression of miR-143 in both primary
CRC tissues and CRC cell lines. (A) Decreased miR-143 expression
(log10 scale at Y axis) in CRC tissues compared to the adjacent
normal colonic tissues from a panel of 30 CRC patients (Wilcoxon’s
paired test, P = 0.006). (B) Significant loss of miR-143 expression in
six CRC cell lines in comparison with control normal colonic mucosa
pooled from 3 healthy individuals. Figure is representative of 3
experiments with similar results.
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significantly lower MACC1 protein expression (Figure
2B) and higher miR-143 expression (Figure 2C) com-
pared to SW620 cells, we selected these two cell lines to
verify our hypothesis. We transfected SW620 cells or
SW480 cells with miR-143 mimics or inhibitors at a
concentration of 50 nM. Western blot showed that, at
48 h after transfection, the enhanced miR-143 in SW620
cells significantly repressed MACC1 protein expression
compared to cells transfected with scramble control
(Figure 2E). Relatively, downregulation of miR-143 by
inhibitors in SW480 cells led to a moderate increase of
MACC1 protein level (Figure 2E). Meanwhile, apparent
alterations of MACC1 mRNA expression were also
observed by quantitative PCR (Figure 2E). It suggested a
potential regulation of MACC1 by miR-143. To further
investigate if the predicted binding site of miR-143 to
3’UTR of MACC1 is responsible for this regulation, we
cloned the 3’UTR of MACC1 downstream to a lucifer-
ase reporter gene (wt-MACC1), its mutant version
(mut-MACC1) by the binding site mutagenesis was also
constructed. We co-transfected wt-MACC1 vector and
miR-143 mimics or scramble control into HEK293 cells.
The luciferase activity of miR-143 transfected cells was
significantly reduced compared to scramble control cells
(Figure 2D). Moreover, miR-143-mediated repression of
luciferase activity was abolished by the mutant putative
binding site (Figure 2D). These results suggested miR-
143 could inhibit MACC1 expression at transcriptional
level.
Effect of miR-143 on CRC cell growth, migration and
invasion
To validate if miR-143 regulates CRC cell growth, we
performed a proliferation assay by transfecting miR-143
mimics or scramble control into SW620 cells. It showed
that the increased expression of miR-143 induced signif-
icant inhibition on cell growth (Figure 3A). Correspond-
ingly, after transfected with miR-143 inhibitors, SW480
cells presented stimulated cell growth compared to
scramble control (Figure 3C). Cell motility of transfected
Figure 2 miR-143 directly targets MACC1 by binding to its 3’UTR. (A) The predicted miR-143 binding site within MACC1 3’UTR and its
mutated version by site mutagenesis are as shown. (B) Variable MACC1 expression in six CRC cell lines was obtained by Western blot. b-actin
was used as the loading control. (C) Non-metastatic SW480 cells expressed significantly higher level of miR-143 compared with its metastatic
counterpart SW620 cells (* P < 0.05). (D) The repression of luciferase activity by MACC1 3’UTR was dependent on miR-143. Mutated MACC1
3’UTR abrogated miR-143 mediated repression luciferase activity (** P < 0.01). (E) In comparison with scramble controls, elevated expression of
miR-143 by mimics inhibited MACC1 expression at both mRNA and protein level, while reduction of miR-143 by inhibitors moderately restored
MACC1 expression (* P < 0.05). Figure is representative of 3 experiments with similar results.
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Figure 3 Effects of miR-143 on proliferation, migration and invasion of SW620 and SW480 cell lines. (A) Ectopic expression of miR-143 by
transfecting miR-143 mimics significantly reduced proliferation of SW620 cells, in comparison with parental and scramble controls (* P < 0.05). (B)
Ectopic expression of miR-143 notably inhibited cell migration and invasion of SW620 cells (100 × magnification, * P < 0.05). Inversely, inhibition
of miR-143 expression by transfecting miR-143 inhibitors simultaneously (C) promoted proliferation (*P < 0.05) and (D) stimulated cell migration
and invasion of SW480 cells, compared with parental and scramble controls (100 × magnification, * P < 0.05). Figure is representative of 3
experiments with similar results.
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cells was also evaluated by migration and invasion
assays. As shown in Figure 3B, compared to the scram-
ble control, miR-143 mimics transfected SW620 cells
exhibited significant impairment of migratory ability.
The corresponding effect on invasive ability was also
observed in parallel invasion assay. Inversely, downregu-
lation of miR-143 in inhibitors transfected SW480 cells
apparently promoted cell migration and invasion ability
(Figure 3D).
Knockdown of MACC1 expression repress CRC cell
growth, migration and invasion
To further confirm the potential relationship between
miR-143 and the downstream gene MACC1, we tested
cell growth and motility under the condition of siRNA
mediated knockdown of MACC1 gene. Once MACC1
expression was effectively depressed by siRNA (Figure
4A), transfected SW620 cells exhibited decreased cell
growth (Figure 4B), impaired cell migration and invasion
ability (Figure 4C), which was in consistent with the
inhibitory effects induced by downregulation of miR-
143. Furthermore, when treating SW620 cells with
MACC1 siRNA in combination with miR-143 mimics,
we observed synergistic inhibitory effects on MACC1
expression (Figure 4A), cell growth (Figure 4B), cell
migration and invasion ability (Figure 4C), compared to
either MACC1 siRNA or miR-143 mimics treatment
alone. Taken together, these results indicated that miR-
143 functions as a potent tumor suppressor through
regulating MACC1 expression.
Correlation of expression between miR-143 and MACC1
To confirm the relevance between miR-143 and
MACC1 expression, we investigated the expressions of
miR-143 and MACC1 mRNA in the six CRC cell lines
and the small panel of 9 paired primary CRC and nor-
mal adjacent colonic tissues. In all CRC cell lines, an
inverse correlation of expression between miR-143 and
MACC1 mRNA was observed (Figure 4D). In the ana-
lyzed panel of 9 CRC patients, all the tumor tissues
showed a notable decreased expression of miR-143 com-
pared to their matched adjacent normal tissues. We also
observed an inverse correlation between miR-143 and
MACC1 expression in CRC tissues and their adjacent
normal tissues (Figure 4E).
Discussion
Most of deaths from cancer are caused by complications
arising from metastasis. Therefore, targeting metastatic
disease is a pivotal anti-cancer strategy. Studies on
tumor invasion and metastasis have revealed the critical
role of miRNA in these processes by the mechanism
that miRNA could regulate a variety of genes pivotal for
invasion or metastasis [23,24]. Quite recently, some
miRNAs have been identified to promote [25-27] or
suppress [28-30] tumor invasion or metastasis, providing
potential therapeutic targets on anti-metastasis strategy.
In CRC, miR-21 has been demonstrated to enhance cel-
lular invasion, intravasation and metastasis through
post-transcriptionally suppressing PDCD4 gene [31]. By
targeting Cdc42, miR-137 exerted inhibitory effect on
CRC cell invasion [32]. Of these deregulated miRNA in
CRC specific miRNA profile, miR-143 was steadily
downregulated in the whole CRC succession from ade-
nomatous to cancer [12]. Further studies showed that
miR-143 was tumor invasion front-specific downregu-
lated in CRC, and associated with aggressive mucinous
phenotype in CRC [33,34]. In a mouse colorectal carci-
noma xenograft study, overexpression of miR-143 could
impair tumor growth by induction of apoptosis and
inhibition of proliferation [35]. Based on these findings,
we speculated miR-143 might be involved in CRC meta-
static processes. Finally, we confirmed the link between
miR-143 and MACC1, a positive CRC metastasis related
gene, and found that miR-143 inhibited CRC cell inva-
sion and migration via targeting MACC1.
Our results obtained from quantitative PCR validation
that miR-143 was commonly downregulated in CRC cell
lines and in 32 out of 39 (82.1%) enrolled CRC patients,
were in consistent to previous studies. Of these analyzed
CRC tissues, we found that miR-143 downregulation
was not associated with clinical characteristics of
patients (data not shown). Since SW620 cells had a
pretty lower expression of miR-143 compared to SW480
cells, which were derived from the same patient as
SW620, we selected these two cell lines to perform
further in vitro function assays. We restored miR-143
expression in SW620 cells and found that miR-143
inhibited cell proliferation, invasion and migration. On
the contrary, when transfected with miR-143 inhibitors,
SW480 cells exhibited stimulated proliferation as well as
invasion and migration capabilities. These findings sug-
gested that miR-143 was involved in the processes of
metastasis.
MACC1, reported by Stein et al. [16], was identified to
be an independent prognostic indicator of metastasis
formation and metastasis-free survival. MACC1-based
positive and negative prediction of metachronous metas-
tasis was correct to 74% and 80% respectively [36].
Mechanically, MACC1 transcriptionally activated Met to
promote HGF/Met signaling pathway, which has been
reported essential for tumorigenesis and metastasis. Our
results confirmed a vital molecular relationship between
miR-143 and MACC1. We showed that, at both mRNA
and protein level, upregulation of miR-143 expression in
SW620 cells effectively suppressed MACC1 expression,
whereas, in SW480 cells, downregulation of miR-143
moderately promoted MACC1 expression. It suggested a
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Figure 4 Functional effects of MACC1 downregulation on SW620 cells. Inverse correlation between miR-143 and MACC1 expression in CRC.
(A) Effectively suppression of MACC1 protein expression by MACC1 siRNA and miR-143 mimics respectively and combinedly. Note the more
efficient suppression of MACC1 induced by combined treatment. Suppression of MACC1 simultaneously resulted in (B) significant inhibition of
cell growth and (C) cell migration and invasion (100 × magnification) of SW620 cells compared with negative controls. Note the synergistic
inhibitory effect induced by combination of MACC1 siRNA and miR-143 mimics, compared with either of them alone (*P < 0.05). The correlation
between miR-143 and MACC1 mRNA expression by scatter plot. (D) An inverse correlation was observed in six CRC cell lines (Spearman’ s
correlation, r = -0.943, P = 0.005), and (E) also observed in another independent panel of 9 paired CRC tissues and adjacent normal tissues
(Spearman’s correlation, r = -0.48, P = 0.044). Figure is representative of 3 experiments with similar results.
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potential inverse relevance of miR-143 and MACC1 in
CRC. Loss-of-function study of MACC1 by siRNA-
mediated knockdown demonstrated suppressive effects
on cellular proliferation, invasion and migration, which
were also verified in gain-of-function study by enhanced
miR-143 expression. Furthermore, by luciferase reporter
study, we verified that miR-143 directly target MACC1
gene through binding to specific complementary site
within its 3’ untranslated region. In addition, the inverse
correlation of expression between miR-143 and MACC1
expression in CRC cell lines and tissues indicated that,
decreased expression of miR-143 may account for upre-
gulation of MACC1 in CRC development. Taken
together, these findings sufficiently consolidated that
miR-143 played a suppressive role in cellular prolifera-
tion, migration and invasion, at least, in part due to
directly inhibiting MACC1 expression.
Activation of HGF/Met signaling pathway leads to mul-
tiple malignant processes, including cell growth, EMT,
angiogenesis, cell motility, invasiveness, and metastasis
[37]. Stein et al. [16] reported a MACC1-driven positive
feedback loop in CRC metastasis that MACC1 translo-
cated into nuclear following HGF treatment and bound
to the Met promoter to activate HGF/Met signaling. In
xenograft model study, they showed that knockdown of
MACC1 by si/shRNA resulted in significant reduction of
tumor size and number of liver metastases. That sug-
gested targeting MACC1 was a promising strategy in pre-
vention of CRC metastasis. Our study revealed the
inhibitory effect of miR-143 on MACC1, and partly eluci-
dated a potential molecular mechanism by which miR-
143 participated in CRC agrressiveness.
More recently, Hurst et al. [38] proposed a novel field
of cancer-related miRNAs termed metastamir that are
associated with metastatic processes. For example, miR-
21 is a mastermind of metastasis that promotes cell sur-
vival, migration, invasion, in vivo intravasasion and
metastasis [39-41], whereas miR-200 family is delin-
quent whose absence contributes to EMT phenotype
[42-44]. These metastamir represent potential candidate
cancer prognostic markers and therapeutic targets for
metastatic cancers. Our findings suggest that miR-143
could function as a metastamir via targeting MACC1.
In conclusion, we newly described miR-143/MACC1
link and provided a potential mechanism for MACC1
dysregulation and contribution to CRC cell invasion. As
a result, restoration of miR-143 expression could have
an important implication for the clinical management of
CRC.
Materials and methods
Tissue samples, cell lines and cell transfection
A total of 39 pairs of primary CRC and their matched
adjacent normal colonic epithelial tissues were collected
and randomly divided into a large panel of 30 pairs and
a small panel of 9 pairs. All samples were obtained from
patients who underwent surgical resections at Nanfang
Hospital (Guangzhou, China) and snap-frozen in liquid
nitrogen, then stored at -80°C for further use. This pro-
ject was approved by the Ethic Committee of Nanfang
hospital.
Six human colorectal cancer (CRC) cell lines, includ-
ing LoVo, HT29, SW480, SW620, Caco-2 and HCT116,
were purchased from American Type Culture Collec-
tion. Cells were grown routinely in RPMI-1640 medium
(Invitrogen, CA, USA) supplemented with 10% fetal
bovine serum (Gibco, CA, USA) and cultured in a 37°C
humidified atmosphere of 5% CO2.
Ectopic expression of miR-143 in cells was achieved
by transfection with miR-143 mimics or inhibitors (Gen-
epharma, Shanghai, China) using Lipofectamine2000
(Invitrogen, CA, USA). Knockdown of MACC1 was per-
formed using MACC1 siRNA (Genepharma, Shanghai,
China). Cells were plated in 6-well clusters or 96-well
plates and transfected for 24 h or 48 h. Transfected cells
were used in further assays or RNA/protein extraction.
RNA extraction and SYBR green quantitative PCR analysis
Total RNA was extracted from cells using Trizol reagent
(Invitrogen, CA, USA). Mature miR-143 expressions in
cells were detected using a Hairpin-it TM miRNAs
qPCR kit (Genepharma, Shanghai, China). Expression of
RNU6B was used as an endogenous control. MACC1
expression was measured by SYBR green qPCR assay
(Takara, Dalian, China). Data were processed using 2-
ΔΔCT method.
CCK-8 cell proliferation assay
Cell proliferation rates were measured using Cell Count-
ing Kit-8 (CCK-8) (Beyotime, Hangzhou, China). 0.5 ×
104 cells were seeded in each 96-well plate for 24 h,
transfected with the indicated miRNA or siRNA, and
further incubated for 24 h, 48 h, 72 h and 96 h respec-
tively. 10 μl CCK-8 reagent was added to each well at 1
h before the endpoint of incubation. OD450nm value in
each well was determined by a microplate reader.
Cell invasion and migration assay
The invasive and migratory potential of cells was evalu-
ated using transwell inserts with 8 μm pores (Coring,
NY, USA). For invasion assay, at 24 h after transfection,
3.0 × 105 cells in serum free medium were added to
each upper insert pre-coated with matrigel matrix (BD,
NJ, USA). 500 μl 10% FBS medium was added to the
matched lower chamber. After 48 h incubation, non-
invaded cells were removed from the upper surface of
the transwell membrane with a cotton swab, and
invaded cells on the lower membrane surface were fixed
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in methanol, stained with 0.1% crystal violet, photo-
graphed, and counted. For migration assay, the proce-
dures were similar, except that 2 × 105 cells were added
into the insterts without matrix gel pre-coated. Six ran-
dom fields at 100 × magnification for each insert were
counted. Inserts were conducted in triplicate in three
separate experiments.
Western blot analysis
Immunoblotting was performed to detect the expression
of MACC1 in CRC cell lines. Cultured or transfected
cells were lysed in RIPA buffer with 1% PMSF. Protein
was loaded onto a SDS-PAGE minigel and transferred
onto PVDF membrane. After probed with 1:1000 diluted
rabbit polyclonal MACC1 antibody (Abcam, MA, USA)
at 4°C overnight, the blots were subsequently incubated
with HRP-conjugated secondary antibody (1:5000). Sig-
nals were visualized using ECL Substrates (Millipore,
MA, USA). b-actin was used as an endogenous protein
for normalization.
Luciferase reporter assay
A fragment of 3’UTR of MACC1 (1022 bp) containing
the putative miR-143 binding site was amplified by PCR
using following primers:
wt-MACC1 (forward) 5’ CCGCTCGAGCACCAG-
TAAAACAAGGAACTTG 3’
wt-MACC1 (reverse) 5’ GAATGCGGCCGCTTTA-
CAGAAACAAATGCAATGTTAC 3’
The PCR product was subcloned into a psiCHECK-2
vector (Promega, Madison, WI) immediately down-
stream to the luciferase gene sequence. A psiCHECK-2
construct containing 3’UTR of MACC1 with a mutant
seed sequence of miR-143 was also synthesized using
the primers:
mut-MACC1 (forward) 5’ TTAAAATTTCC-
TACTTGTGTATAGAAATGGAAAG 3’
mut-MACC1 (reverse) 5’ ACAAGTAGGAAATTT-
TAATACAGTGGTTCTC 3’
All constructs were verified by DNA sequencing.
HEK293 cells were plated in 96-well clusters, then co-
transfected with 100 ng constructs with or without miR-
143 precursors. At 48 h after transfection, luciferase
activity was detected using a dual-luciferase reporter
assay system (Promega, Madison, WI) and normalized
to Renilla activity.
Statistical analysis
All data from 3 independent experiments were
expressed as mean ± SD and processed using SPSS 13.0
statistical software. The expression of miR-143 in CRC
tissues and paired adjacent normal colonic tissues were
compared by Wilcoxon’s paired test. The difference
among the groups in migration and invasion assay was
estimated by Student’s t-test or one-way ANOVA. A P-
value of < 0.05 was considered to be statistically
significant.
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Acknowledgements
We thank Guang Yang. MD (Xi’an Jiaotong University) for the support on
bioinformatics and biostatistics.
Authors’ contributions
YZ and ZQW designed research and analyzed data. ZQW, MC, LP, XYW, QYM
and FLM carried out molecular biology studies. YZ and BJ wrote the paper.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 December 2011 Accepted: 25 April 2012
Published: 25 April 2012
References
1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60:277-300.
2. Filipowicz W: RNAi: The nuts and bolts of the RISC machine. Cell 2005,
122:17-20.
3. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350-355.
4. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity:
microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009,
11:228-234.
5. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer 2006, 6:259-269.
6. Hwang HW, Mendel JT: MicroRNAs in cell proliferation, cell death, and
tumorigenesis. Br J Cancer 2006, 94:776-780.
7. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005, 120:15-20.
8. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-
Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR,
Golub TR: MicroRNA expression profiles classify human cancers. Nature
2005, 435:834-838.
9. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev
Cancer 2006, 6:857-866.
10. Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, Kitade Y, Naoe T,
Akao Y: MicroRNA-143 functions as a tumor suppressor in human
bladder cancer T24 cells. Cancer Lett 2010, 2:211-220.
11. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, Li P, Zhang W, Wu H, Feng N,
Wang Z, Hua L, Wang X: miR-143 decreases prostate cancer cells
proliferation and migration and enhances their sensitivity to docetaxel
through suppression of KRAS. Mol Cell Biochem 2011, 1-2:207-213.
12. Micheal MZ, O’Connor SM, Van holst pellekan NG, Young GP, James RJ:
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol
Cancer Res 2003, 1:882-891.
13. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G,
Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J, Zhang CY:
Role of miR-143 targeting KRAS in colorectal ltumorigenesis. Oncogene
2009, 10:1385-1392.
14. Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ, Röcken C, Ebert MP, Kwok TT,
Sung JJ: MicroRNA-143 targets DNA methyltransferases 3A in colorectal
cancer. Br J Cancer 2009, 101:699-706.
15. Kulda V, Pesta M, Topolcan O, Liska V, Treska V, Sutnar A, Rupert K,
Ludvikova M, Babuska V, Holubec L Jr, Cerny R: Relevance of miR-21 and
Zhang et al. Molecular Cancer 2012, 11:23
http://www.molecular-cancer.com/content/11/1/23
Page 8 of 9
miR-143 expression in tissue samples of colorectal carcinoma and its
liver metastases. Cancer Genet Cytogenet 2010, 2:154-160.
16. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W,
Schlag PM: MACC1, a newly identified key regulator of HGF/Met
signaling, predicts colon cancer metastasis. Nat Med 2009, 15:59-67.
17. Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T,
Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K: MACC 1 as a
marker for peritoneal-disseminated gastric carcinoma. Anticancer Res
2010, 9:3441-3444.
18. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T,
Yasumoto K: Overexpression of MACC1 mRNA in lung adenocarcinoma is
associated with postoperative recurrence. J Thorac Cardiovasc Surg 2011,
4:895-898.
19. Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, Saito M,
Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K: MACC 1 as a marker
for vascular invasive hepatocellular carcinoma. Anticancer Res 2011,
3:777-780.
20. Leibovitz A, Stinson JC, McCombs WB, McCoy CE, Mazur KC, Mabry ND:
Classification of human colorectal adenocarcinoma cell lines. Cancer Res
1976, 36:4562-4569.
21. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø:
Twelve colorectal cancer cell lines exhibit highly variable growth and
metastatic capacities in an orthotopic model in nude mice. Eur J Cancer
2004, 40:1593-1598.
22. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW,
Stetler-Stevenson WG: Validation of a model of colon cancer progression.
J Pathol 2000, 192:446-454.
23. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J,
Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some
microRNAs downregulate large numbers of target mRNAs. Nature 2005,
433:769-773.
24. Dalmay T, Edwards DR: MicroRNAs and the hallmarks of cancer. Oncogene
2006, 25:6170-6175.
25. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-
Saenz De Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N,
Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, Osman I,
Hernando E: miR-30b/30d regulation of GalNAc transferases enhances
invasion and immunosuppression during metastasis. Cancer Cell 2011,
20:104-118.
26. Yang CH, Yue J, Pfeffer SR, Handorf CR, Pfeffer LM: MicroRNA-21 regulates
the metastatic behavior of B16 melanoma cells. J Biol Chem 2011,
45:39172-39178.
27. Oneyama C, Morii E, Okuzaki D, Takahashi Y, Ikeda J, Wakabayashi N,
Akamatsu H, Tsujimoto M, Nishida T, Aozasa K, Okada M: MicroRNA-
mediated upregulation of integrin-linked kinase promotes Src-induced
tumor progression. Oncogene 2011, doi: 10.1038/onc.2011.367.
28. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X: miR-34a inhibits
migration and invasion by down-regulation of c-Met expression in
human hepatocellular carcinoma cells. Cancer Lett 2009, 275:44-53.
29. Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY,
Zhuang SM: MicroRNA-29b suppresses tumor angiogenesis, invasion and
metastasis by regulating MMP-2 expression. Hepatology 2011,
54:1729-1740.
30. Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z,
Xu H: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by
targeting Bcl-w and specificity protein 1. Oncogene 2011, doi: 10.1038/
onc.2011.340.
31. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S,
Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates
tumor suppressor Pdcd4 and stimulates invasion, intravasation and
metastasis in colorectal cancer. Oncogene 2008, 15:2128-2136.
32. Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q, Chen J, Chen X, Zhang S, Liu Z,
Zhou J, Zhu Y, Deng Y, Zheng Y, Bi F: miR-137 targets Cdc42 expression,
induces cell cycle G1 arrest and inhibits invasion in colorectal cancer
cells. Int J Cancer 2011, 6:1269-1279.
33. Kahlert C, Klupp F, Brand K, Lasitschka F, Diederichs S, Kirchberg J,
Rahbari N, Dutta S, Bork U, Fritzmann J, Reissfelder C, Koch M, Weitz J:
Invasion front-specific expression and prognostic significance of
microRNA in colorectal liver metastases. Cancer Sci 2011, doi:10.1111/
j.1349-7006.
34. Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M,
McAnena OJ, Kerin MJ: MicroRNA signature analysis in colorectal cancer:
identification of expression profiles in stage II tumors associated with
aggressive disease. Int J Colorectal Dis 2011, doi: 10.1007.
35. Borralho PM, Simões AE, Gomes SE, Lima RT, Carvalho T, Ferreira DM,
Vasconcelos MH, Castro RE, Rodrigues CM: miR-143 Overexpression
Impairs Growth of Human Colon Carcinoma Xenografts in Mice with
Induction of Apoptosis and Inhibition of Proliferation. PLoS One 2011, 8:
e23787.
36. Arlt F, Stein U: Colon cancer metastasis: MACC1 and Met as metastatic
pacemakers. Int J Biochem Cell Biol 2009, 12:2356-2359.
37. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis,
motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925.
38. Hurst DR, Edmonds MD, Welch DR: Metastamir: the field of metastasis-
regulatory microRNA is spreading. Cancer Res 2009, 69:7495-7498.
39. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic factor
in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
40. Asangani IA, Rasheed SA, Nikolova SA, Leupold JH, Colburn NH, Post S,
Allgayer H: MicroRNA-21 (miR-21) posttranscriptionally downregulates
tumor suppressor Pdcd4 and stimulates invasion, intravasation and
metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
41. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr, Lazo JS, Wang Z,
Zhang L, Yu J: MicroRNA-21 negatively regulates Cdc25A and cell cycle
progression in colon cancer cells. Cancer Res 2009, 69:8157-8165.
42. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA,
Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate
epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat
Cell Biol 2008, 10:593-601.
43. Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-
mesenchymal transition and cancer cell migration by direct targeting of
E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008,
283:14910-14914.
44. Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the
epithelial phenotype of cancer cells by targeting the E-cadherin
repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
doi:10.1186/1476-4598-11-23
Cite this article as: Zhang et al.: MicroRNA-143 Targets MACC1 to Inhibit
Cell Invasion and Migration in Colorectal cancer. Molecular Cancer 2012
11:23.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. Molecular Cancer 2012, 11:23
http://www.molecular-cancer.com/content/11/1/23
Page 9 of 9
